THE MCMANUS GROUP for BRISTOL-MYERS SQUIBB
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to Center for Medicare and Medicaid Innovation (CMMI) guardrails Issues related to CMS fixed-dose combination drugs for Initial Price Applicability Year 2029 (CMS-4215-P)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| ALEX WHALEN | — |
Health Issues HCR
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| ALEX WHALEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.